Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00293150 · ClinicalTrials.gov registry record · Phase 4
Reversing Endothelial and Diastolic Dysfunction and Improving Collagen Turnover in Diastolic Heart Failure
A Phase 4 study, sponsored by The Cleveland Clinic.
- Terminated
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT00293150 is a Phase 4 study that was terminated before completion, run by The Cleveland Clinic. The registered enrollment target is 11 participants.
The verdict
NCT00293150, a Phase 4 study, was terminated before completion, sponsored by The Cleveland Clinic.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
The principle aim is to determine the efficacy of eplerenone in patients with diastolic heart failure to reverse cardiac remodeling and to improve diastolic function.
Interventions
- DRUG Eplerenone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2003-09 |
| Est. Completion | 2007-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00293150
The ClinicalTrials.gov registry entry for NCT00293150 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Eplerenone is the first listed.
NCT00293150 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00293150 about?
NCT00293150 is a clinical study titled "Reversing Endothelial and Diastolic Dysfunction and Improving Collagen Turnover in Diastolic Heart Failure". The principle aim is to determine the efficacy of eplerenone in patients with diastolic heart failure to reverse cardiac remodeling and to improve diastolic function.
What is the current status of trial NCT00293150?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2003-09. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00293150?
The interventions under investigation include: Eplerenone (DRUG).
Who is sponsoring clinical trial NCT00293150?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.